Clinical trials · Massachusetts
Relapsed or Refractory Multiple Myeloma clinical trials in Massachusetts
We’re tracking 115 recruiting relapsed or refractory multiple myeloma studies with a site in Massachusetts — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in Massachusetts
- NCT05319314RecruitingPhase 1/Phase 2
Study drug for advanced colon cancer that has come back or failed
This Phase 1/2 trial tests LYL273, a new targeted treatment, for people with metastatic colorectal (colon) cancer that has returned or not responded to standard chemo. It’s designed to see how well the drug can control the cancer and what side effects it causes.
Boston, MassachusettsAges 18 years+ - NCT05139017RecruitingPhase 2/Phase 3
Test drug Zilovertamab vedotin with standard care for lymphoma
This trial studies zilovertamab vedotin added to standard chemotherapy for people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It may help by targeting lymphoma cells and improving how well standard treatment works after prior treatments have failed.
Boston, MassachusettsAges 18 years+ - NCT04988555RecruitingPhase 1/Phase 2
Study of an investigational drug for high-risk acute leukemia
This Phase 1/2 study tests enzomenib (DSP-5336) in people with relapsed or hard-to-treat acute leukemia (and, in some places, certain other blood cancers). The goal is to see how the drug works and how safe it is, especially for leukemia cases with specific genetic changes (KMT2A/MLL or NPM1).
Boston, MassachusettsAges 12 years+ - NCT04792489RecruitingPhase 2
CAR-T cell therapy for aggressive B-cell lymphomas
This trial tests a new CAR-T cell treatment (MB-CART2019.1) for people with certain types of aggressive B-cell non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to prior treatments. It aims to see if this therapy can help when other options have failed.
Boston, MassachusettsAges 18 years+ - NCT04421560RecruitingPhase 1/Phase 2
Testing pembrolizumab, ibrutinib, and rituximab for PCNSL
This Phase 1/2 study tests how well a combination of pembrolizumab, ibrutinib, and rituximab treats primary CNS lymphoma that came back or didn’t respond after prior brain treatment. It may help shrink the lymphoma and control it in the brain and fluid around the brain.
Boston, MassachusettsAges 18 years+ - NCT03013998RecruitingPhase 2/Phase 3
Personalized treatment study for acute myeloid leukemia
This study matches people with acute myeloid leukemia (AML) to treatments based on their specific genetic markers. It aims to find the most effective therapy with fewer side effects compared to standard care.
Boston, MassachusettsAges 18 years+ - NCT02974647RecruitingPhase 2
Ruxolitinib for relapsed or hard-to-treat T/NK cell lymphoma
This trial studies ruxolitinib, a medicine that affects immune signaling, in people whose T-cell or NK-cell lymphoma has returned or hasn’t responded to treatment. It may help shrink lymphoma and improve symptoms after other therapies.
Boston, MassachusettsAges 18 years+ - NCT02074839RecruitingPhase 1
Oral AG-120 for advanced blood cancers with an IDH1 mutation
This Phase 1 study tests an oral medicine called AG-120 in adults with advanced blood cancers that have a specific IDH1 mutation. It also looks at safety and how the treatment works, with frequent blood, urine, and bone marrow samples.
Boston, MassachusettsAges 18 years+ - NCT04851119RecruitingPhase 1/Phase 2
Tegavivint for kids and young adults with hard-to-treat solid tumors
This early-phase study tests tegavivint to see how well it works and how safe it is for children and young adults with solid cancers that have come back or are not responding. It may be an option if your tumor type (including certain lymphomas or desmoid tumors) matches the study’s rules.
Boston, MassachusettsAges 1–30 - NCT06484062RecruitingPhase 1
Testing cirtuvivint alone and with ASTX727 for leukemia and MDS
This trial tests a new drug called cirtuvivint, given alone or with another drug (ASTX727), for people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) that has come back or not responded to treatment, and for people with high-risk MDS who have not been treated before. The goal is to see if these combinations work better than current options.
Boston, MassachusettsAges 18 years+ - NCT06441617Enrolling by invitation
Online program to reduce fatigue in multiple sclerosis
This trial tests an online self-management program to help reduce fatigue in people with MS. You'll use a website or app over 24 weeks, and researchers will check how well it works.
Waltham, MassachusettsAges 22 years+ - NCT06247787RecruitingPhase 1
Imetelstat plus chemo for relapsed leukemia in kids
This trial tests a new drug called imetelstat combined with two chemotherapy drugs (fludarabine and cytarabine) for children and teens with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or juvenile myelomonocytic leukemia (JMML) that has come back or not responded to treatment. The goal is to find the safest dose of imetelstat and see if it helps control the cancer.
Boston, MassachusettsAges 1–18 - NCT04616560RecruitingPhase 2
New drug for recurrent Wilms tumor, osteosarcoma, and DSRCT
This trial tests a targeted drug called trastuzumab deruxtecan for children and young adults with certain cancers that have come back or not responded to treatment. It may help if your tumor has not responded to standard therapies.
Boston, MassachusettsAges 12–39 - NCT07325292RecruitingPhase 3
Frexalimab injection vs IV for multiple sclerosis
This study tests if a new injection (frexalimab) works as well as the IV version for people with relapsing or certain types of secondary progressive multiple sclerosis. It could offer a more convenient way to receive this treatment at home.
Foxborough, MassachusettsAges 18–60 - NCT07299019RecruitingPhase 3
Study of orelabrutinib for secondary progressive MS
This study tests an oral medication called orelabrutinib for people whose multiple sclerosis has changed from relapsing-remitting to secondary progressive. The goal is to see if it can slow down disability worsening that happens even without relapses.
Boston, MassachusettsAges 18–60 - NCT07225504RecruitingPhase 3
Study of remibrutinib for secondary progressive multiple sclerosis
This trial tests an oral medication called remibrutinib to see if it can slow disability progression in people with secondary progressive multiple sclerosis (SPMS). You might join if you have had MS for a while, your symptoms have worsened over the past year, and you haven't had any recent relapses.
Foxborough, MassachusettsAges 18–65 - NCT07011914Recruiting
MS care study for young adults
This study looks at how to improve care for young adults with relapsing-remitting MS. It focuses on people who are Black, Hispanic, or have limited income.
Boston, MassachusettsAges 18 years+ - NCT06554340Recruiting
Exercise study for multiple sclerosis with high blood pressure
This study tests if exercise can improve blood vessel health and daily function in people with multiple sclerosis (MS) who also have high blood pressure. It may help you move better and feel better.
Boston, MassachusettsAges 18 years+ - NCT06136728RecruitingPhase 3
Dalfampridine and physical therapy for walking problems in MS
This trial tests whether adding dalfampridine to physical therapy helps people with multiple sclerosis walk better. You must not already be taking dalfampridine or getting physical therapy to join.
Boston, MassachusettsAges 25–75 - NCT03739814RecruitingPhase 2
Test inotuzumab, blinatumomab, and possibly ponatinib for CD22 ALL
This Phase 2 study tests a combination of medicines (inotuzumab ozogamicin and blinatumomab), with or without ponatinib, for people with CD22-positive B-cell acute lymphoblastic leukemia (ALL). It aims to improve remission and control leukemia cells, including in the bone marrow.
Springfield, MassachusettsAges 18 years+ - NCT02649985RecruitingPhase 1/Phase 2
PET brain scan study for several brain and mood conditions
This early-phase study uses PET and MRI brain scans to better understand brain changes in multiple sclerosis, Alzheimer’s disease, and other neurological or mood conditions. The goal is to test whether these scans can show disease-related differences and guide future treatments.
Boston, MassachusettsAges 18–85 - NCT06223880RecruitingPhase 4
AXS-05 vs Bupropion to prevent depression relapse
This study tests whether a new drug called AXS-05 can prevent depression from coming back, compared to an older drug called bupropion. If you have major depression and are at risk of relapse, this trial may help you stay well.
Boston, MassachusettsAges 18–65 - NCT07439211RecruitingPhase 1
Testing a new drug combo for acute myeloid leukemia
This trial tests a new drug, eganelisib, combined with azacitidine and venetoclax for patients with acute myeloid leukemia (AML). It's for people whose AML has come back or hasn't responded to treatment, or for those with a high-risk type who haven't been treated yet.
Boston, MassachusettsAges 18–90 - NCT07374029RecruitingPhase 1
T cell therapy with vaccine, decitabine, and venetoclax in AML
This trial tests a treatment that combines a personalized vaccine made from your leukemia cells and your own immune cells (T cells) with standard chemotherapy drugs (decitabine and venetoclax). The goal is to help your immune system better fight the leukemia.
Boston, MassachusettsAges Any age
Relapsed or Refractory Multiple Myeloma trials by city in Massachusetts
Where these studies are running in Massachusetts
Institutions with a site for the recruiting relapsed or refractory multiple myeloma studies listed above.
- Dana-Farber Cancer Institute · 11 studies
- Massachusetts General Hospital · 3 studies
- Beth Israel Deaconess Medical Center · 2 studies
- Boston Clinical Trials
- Brigham and Women's Hospital
- Brigham MS Center, 60 Fenwood Road
- Clinical Research Site
- Elliot Lewis MS Center
What taking part in a relapsed or refractory multiple myeloma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Relapsed or Refractory Multiple Myeloma trials in other states
Common questions
- Are there relapsed or refractory multiple myeloma clinical trials in Massachusetts?
- Yes. We're currently tracking 115 recruiting relapsed or refractory multiple myeloma studies with a site in Massachusetts, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a relapsed or refractory multiple myeloma study in Massachusetts?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Massachusetts to take part?
- Not necessarily. These studies have a site in Massachusetts, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a relapsed or refractory multiple myeloma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New relapsed or refractory multiple myeloma studies open in Massachusetts regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.